Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 06, 2018 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Participate in Investor Conferences in February

NEWARK, Calif., Feb. 06, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
February 01, 2018 16:01 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEWARK, Calif., Feb. 01, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
January 30, 2018 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces Pricing of Public Offering of Common Stock

NEWARK, Calif., Jan. 30, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
January 29, 2018 16:44 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces Proposed Public Offering of Common Stock

NEWARK, Calif., Jan. 29, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
January 08, 2018 08:00 ET | Source: CymaBay Therapeutics, Inc.

Enrollment Begins in Long-Term Extension Study of Seladelpar in Patients with Primary Biliary Cholangitis

Study allows continued access to long-term treatment with seladelpar in support of the phase 3 registration programPatients currently enrolling have now completed one year of treatment in the phase 2...
January 08, 2018 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Receives $5 Million Milestone Payment for Arhalofenate from Kowa Pharmaceuticals America

NEWARK, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
January 02, 2018 16:01 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

NEWARK, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
December 04, 2017 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Strengthens Management Team with Appointment of Paul Quinlan as General Counsel

NEWARK, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
December 04, 2017 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Strengthens Management Team with Appointment of Paul Quinlan as General Counsel

NEWARK, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
November 13, 2017 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at Three Investor Conferences

NEWARK, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...